Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4074
Name pancreatic adenocarcinoma
Definition A pancreatic carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Cabozantinib pancreatic adenocarcinoma not applicable detail...
Unknown unknown Gemcitabine + Pimasertib pancreatic adenocarcinoma not applicable detail...
Unknown unknown Gemcitabine + Vandetanib pancreatic adenocarcinoma not applicable detail...
Unknown unknown Gemcitabine + PRI-724 pancreatic adenocarcinoma not applicable detail...
Unknown unknown Capecitabine + Ruxolitinib pancreatic adenocarcinoma not applicable detail...
Unknown unknown CGP57380 pancreatic adenocarcinoma not applicable detail...
BRAF mutant Trametinib pancreatic adenocarcinoma sensitive detail...
Unknown unknown Bevacizumab + Erlotinib + Gemcitabine pancreatic adenocarcinoma no benefit detail...
Unknown unknown GSK1904529A pancreatic adenocarcinoma not applicable detail...
Unknown unknown MK2206 + Selumetinib pancreatic adenocarcinoma no benefit detail...
Unknown unknown Gemcitabine + NSC109555 pancreatic adenocarcinoma not applicable detail...
Unknown unknown BI 853520 pancreatic adenocarcinoma not applicable detail...
Unknown unknown Mogamulizumab + Nivolumab pancreatic adenocarcinoma not applicable detail...
Unknown unknown GSK3368715 pancreatic adenocarcinoma not applicable detail...
Unknown unknown GSK3203591 + GSK3368715 pancreatic adenocarcinoma not applicable detail...
Unknown unknown Adavosertib + Gemcitabine + Radiotherapy pancreatic adenocarcinoma not applicable detail...
SMAD4 loss Hydroxychloroquine pancreatic adenocarcinoma predicted - sensitive detail...
Unknown unknown Everolimus + Ribociclib pancreatic adenocarcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00602602 Phase II Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Gemcitabine Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer Completed
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Recruiting
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated
NCT01013649 Phase II Erlotinib + Gemcitabine Gemcitabine Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Active, not recruiting
NCT01088815 Phase II Gemcitabine + Nab-paclitaxel + Vismodegib Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Completed
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01383538 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Saridegib FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Completed
NCT01420874 Phase I EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Active, not recruiting
NCT01431794 Phase Ib/II Gemcitabine + Nab-paclitaxel + Sonidegib Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Terminated
NCT01473940 Phase I Gemcitabine + Ipilimumab Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed
NCT01485744 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Sonidegib LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer Completed
NCT01488552 Phase Ib/II Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Completed
NCT01489865 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT01506973 Phase Ib/II Hydroxychloroquine Gemcitabine A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer Active, not recruiting
NCT01555489 Phase II Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca Terminated
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01585805 Phase II Veliparib Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT01586611 Phase III Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status
NCT01652976 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Dasatinib Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Active, not recruiting
NCT01660971 Phase I Dasatinib + Erlotinib + Gemcitabine Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Active, not recruiting
NCT01666730 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Metformin Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Completed
NCT01683422 Phase II Capecitabine + Erlotinib + Gemcitabine Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer Completed
NCT01764477 Phase I Gemcitabine + PRI-724 Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Completed
NCT01783171 Phase I Dinaciclib + MK2206 Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery Completed
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed
NCT01804530 Phase I PLX7486 Gemcitabine + Nab-paclitaxel Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed
NCT01858883 Phase I Nab-paclitaxel Filgrastim Itacitinib Gemcitabine Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors Completed
NCT01896869 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer Completed
NCT01908478 Phase I Veliparib Gemcitabine A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer Completed
NCT01921751 Phase II Gemcitabine + Nab-paclitaxel Capecitabine High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Terminated
NCT01924260 Phase I Alisertib + Gemcitabine Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting
NCT01956812 Phase III Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) Terminated
NCT01959672 Phase II Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer Completed
NCT02004262 Phase II Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Completed
NCT02005315 Phase I Gemcitabine + Nab-paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Completed
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
NCT02037230 Phase Ib/II Adavosertib + Gemcitabine Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas Completed
NCT02048384 Phase Ib/II Metformin + Sirolimus Metformin A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer Completed
NCT02077881 Phase Ib/II Indoximod Gemcitabine + Nab-paclitaxel Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Completed
NCT02080260 Phase II Regorafenib A Study of Regorafenib in Advanced Pancreatic Cancer Patients Completed
NCT02117479 Phase III Ruxolitinib Capecitabine Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Terminated
NCT02119663 Phase III Capecitabine Capecitabine + Ruxolitinib A Study of Ruxolitinib in Pancreatic Cancer Patients Terminated
NCT02138383 Phase I Enzalutamide Nab-paclitaxel Gemcitabine Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Completed
NCT02153450 Phase I Metformin Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Completed
NCT02155088 Phase I Alpelisib + Gemcitabine + Nab-paclitaxel BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer Completed
NCT02178436 Phase Ib/II Gemcitabine + Nab-paclitaxel + Selinexor Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Unknown status
NCT02184195 Phase III Olaparib Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO) Active, not recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02194829 Phase Ib/II Paclitaxel Gemcitabine Adavosertib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT02227940 Phase I Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer Completed
NCT02231723 Phase I Gemcitabine + Nab-paclitaxel + Napabucasin A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed
NCT02243371 Phase II GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab Completed
NCT02244489 Phase I Capecitabine Oxaliplatin Momelotinib Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma Terminated
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Active, not recruiting
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02336087 Phase I Gemcitabine + Metformin + Nab-paclitaxel Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT02340117 Phase II SGT-53 Gemcitabine + Nab-paclitaxel Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer Recruiting
NCT02349867 Phase I Gemcitabine + Nab-paclitaxel + Sorafenib + Vorinostat Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients Active, not recruiting
NCT02383433 Phase II Gemcitabine + Regorafenib Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer Terminated
NCT02399137 Phase II Nab-paclitaxel Gemcitabine MM-141 A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer Completed
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT02428270 Phase II GSK2256098 + Trametinib A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer Active, not recruiting
NCT02436668 Phase II Gemcitabine + Nab-paclitaxel Ibrutinib Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed
NCT02451982 Phase Ib/II Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer Recruiting
NCT02472977 Phase Ib/II Nivolumab Ulocuplumab Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Terminated
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02562898 Phase Ib/II Gemcitabine + Ibrutinib + Paclitaxel Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT02570711 Phase II Acalabrutinib Gemcitabine + Nab-paclitaxel Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer Terminated
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed
NCT02575508 Phase Ib/II Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Withdrawn
NCT02608229 Phase I Gemcitabine + Nab-paclitaxel + Ulixertinib BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer Terminated
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed
NCT02620800 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + Nab-paclitaxel + Oxaliplatin Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer Completed
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Active, not recruiting
NCT02648282 Phase II Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer Recruiting
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02650804 Phase II BPM 31510 BPM 31510 + Gemcitabine BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients Completed
NCT02651727 Phase I Gemcitabine + Nab-paclitaxel + VS-4718 Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Terminated
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Active, not recruiting
NCT02675946 Phase I CGX1321 Study of CGX1321 in Subjects With Advanced Solid Tumors Recruiting
NCT02677038 Phase II Olaparib Olaparib in Treating Patients With Stage IV Pancreatic Cancer Active, not recruiting
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Terminated
NCT02734160 Phase I Durvalumab + Galunisertib A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Completed
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed
NCT02826486 Phase II BKT140 + Pembrolizumab BKT140 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT) Active, not recruiting
NCT02847000 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer Completed
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Withdrawn
NCT02890355 Phase II Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Veliparib FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT02902484 Phase Ib/II Gemcitabine + Nab-paclitaxel + Nintedanib Nintedanib Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Recruiting
NCT02907099 Phase II BKT140 + Pembrolizumab Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer Active, not recruiting
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Active, not recruiting
NCT02923921 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin Fluorouracil + Leucovorin + Oxaliplatin Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer Completed
NCT02985125 Phase Ib/II Everolimus + Ribociclib LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy Active, not recruiting
NCT03006302 Phase II CRS-207 + Epacadostat + Pembrolizumab CRS-207 + Cyclophosphamide + Epacadostat + GVAX pancreatic cancer vaccine + Pembrolizumab Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer Recruiting
NCT03086369 Phase Ib/II Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine + Nab-paclitaxel A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Active, not recruiting
NCT03086642 Phase I Talimogene laherparepvec Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer Recruiting
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Active, not recruiting
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting
NCT03104439 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting
NCT03122106 Phase I Personalized cancer vaccine Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Active, not recruiting
NCT03126435 Phase III EndoTAG-1 + Gemcitabine Gemcitabine EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Recruiting
NCT03127124 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + NANT-008 + Oxaliplatin QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer Suspended
NCT03140670 Phase II Rucaparib Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Active, not recruiting
NCT03153410 Phase I Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Recruiting
NCT03190265 Phase II CRS-207 + Ipilimumab + Nivolumab CRS-207 + Cyclophosphamide + GVAX pancreatic cancer vaccine + Ipilimumab + Nivolumab Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Recruiting
NCT03192462 Phase Ib/II MultiTAA-specific T cells TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS) Active, not recruiting
NCT03213626 Phase II Cabozantinib + Erlotinib Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma Recruiting
NCT03214250 Phase Ib/II Gemcitabine + Nab-paclitaxel + Nivolumab APX005M + Gemcitabine + Nab-paclitaxel APX005M + Gemcitabine + Nab-paclitaxel + Nivolumab Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma Active, not recruiting
NCT03245541 Phase Ib/II Durvalumab Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) Suspended
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Recruiting
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Active, not recruiting
NCT03269526 Phase Ib/II EGFRBi-armed autologous activated T cells BATs Treatment for Pancreatic Cancer, Phase Ib/II Recruiting
NCT03277209 Phase I Plerixafor To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Terminated
NCT03281382 Phase I Ad5-yCD/mutTKSR39rep-hIL12 Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer Recruiting
NCT03310632 Phase Ib/II Antroquinonol Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer Recruiting
NCT03316599 Phase I Ficlatuzumab + Gemcitabine + Nab-paclitaxel Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer Active, not recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03331562 Phase II Pembrolizumab Paricalcitol + Pembrolizumab A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Active, not recruiting
NCT03336216 Phase II Cabiralizumab + Gemcitabine + Nab-paclitaxel + Nivolumab Cabiralizumab + Nivolumab Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer Active, not recruiting
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + MM-398 + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting
NCT03344172 Phase II Avelumab + Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134) Terminated
NCT03368963 Phase Ib/II MM-398 + trifluridine/tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting
NCT03373188 Phase I Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Recruiting
NCT03374852 Phase II CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer Withdrawn
NCT03376659 Phase Ib/II Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Recruiting
NCT03387098 Phase Ib/II GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting
NCT03403049 Phase I Cisplatin + Gemcitabine Capecitabine + Gemcitabine Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer Completed
NCT03404960 Phase Ib/II Ipilimumab + Niraparib Niraparib + Nivolumab Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax) Recruiting
NCT03410030 Phase Ib/II Cisplatin + Gemcitabine + Nab-paclitaxel + Vitamin C Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM) Recruiting
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn
NCT03451773 Phase Ib/II Gemcitabine + M7824 M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas Completed
NCT03490760 Phase II Durvalumab Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas Recruiting
NCT03504423 Phase III CPI-613 CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Recruiting
NCT03507452 Phase I BAY2287411 First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin Recruiting
NCT03512756 Phase II Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Recruiting
NCT03519308 Phase I Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Gemcitabine + Nab-paclitaxel + Nivolumab A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer Recruiting
NCT03553004 Phase II Niraparib Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial Recruiting
NCT03563144 Phase II Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin QUILT-3.088: NANT Pancreatic Cancer Vaccine Withdrawn
NCT03563248 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer Recruiting
NCT03586869 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin QUILT-3.080: NANT Pancreatic Cancer Vaccine Active, not recruiting
NCT03597581 Phase I RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies Recruiting
NCT03601923 Phase II Niraparib Niraparib in Patients With Pancreatic Cancer Recruiting
NCT03611556 Phase Ib/II Gemcitabine + Nab-paclitaxel + Oleclumab Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study Active, not recruiting
NCT03649321 Phase Ib/II Cisplatin + Gemcitabine + Nab-paclitaxel Bemcentinib + Cisplatin + Gemcitabine + Nab-paclitaxel Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer Recruiting
NCT03665441 Phase III Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1) Recruiting
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting
NCT03697564 FDA approved Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). Suspended
NCT03699319 Phase II CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer Recruiting
NCT03723915 Phase II Pelareorep + Pembrolizumab Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Active, not recruiting
NCT03767582 Phase Ib/II BMS-813160 + GVAX pancreatic cancer vaccine + Nivolumab BMS-813160 + Nivolumab Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Recruiting
NCT03801915 Phase II MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Recruiting
NCT03816163 Phase II Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Zolbetuximab A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma Recruiting
NCT03816358 Phase Ib/II Anetumab ravtansine + Gemcitabine + Nivolumab Anetumab ravtansine + Nivolumab Anetumab ravtansine + Ipilimumab + Nivolumab Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer Recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Recruiting
NCT03854110 Phase Ib/II Gemcitabine + GP-2250 GP-2250 Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine Recruiting
NCT03872206 Phase Ib/II HPN536 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Recruiting
NCT03891979 FDA approved Ciprofloxacin Metronidazole Pembrolizumab Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Recruiting
NCT03956056 Phase I Neoantigen peptide vaccine + Poly ICLC Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Recruiting
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Recruiting
NCT03970252 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Recruiting
NCT04005690 Phase II Olaparib Cobimetinib Cobimetinib or Olaparib in Treating Patients With Resectable Pancreatic Cancer Recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Recruiting
NCT04050085 Phase I Nivolumab + SD-101 SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer Recruiting
NCT04058964 Phase II PEGPH20 + Pembrolizumab Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer Withdrawn
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting
NCT04083651 Phase II Methylnaltrexone Bromide A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer Recruiting
NCT04092673 Phase Ib/II eFT226 Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Recruiting
NCT04098081 Phase II galeterone + Gemcitabine galeterone 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04104672 Phase I AB680 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Recruiting
NCT04123574 Phase I Talabostat Mesylate A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Recruiting
NCT04132505 Phase I Binimetinib + Hydroxychloroquine Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer Recruiting
NCT04137536 Phase I EGFRBi-armed autologous activated T cells A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Recruiting
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting
NCT04157127 Phase I DC tumor cell lysate vaccine Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (DECIST) Recruiting
NCT04191421 Phase Ib/II Siltuximab + Spartalizumab Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Recruiting
NCT04193904 Phase I MRx0518 A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer Recruiting
NCT04214418 Phase Ib/II Atezolizumab + Cobimetinib + Hydroxychloroquine Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) Not yet recruiting
NCT04327986 Phase Ib/II M7824 + NHS-IL12 Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer Not yet recruiting
NCT04331041 Phase II Defactinib Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma Not yet recruiting
NCT04361162 Phase II Ipilimumab + Nivolumab Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer Not yet recruiting
NCT04386057 Phase II Hydroxychloroquine + LY3214996 LY3214996 LY3214996 +/- HCQ in Pancreatic Cancer Recruiting
NCT04387071 Phase Ib/II INCAGN01949 + QbG10 CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Not yet recruiting
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting
NCT04409002 Phase II Dostarlimab + Niraparib Niraparib + Dostarlimab + RT in Pancreatic Cancer Not yet recruiting